Picture [iito] No Tracking 650x80px
Document › Details

SmartDyeLivery GmbH. (5/3/18). "Press Release: Nanoparticles for Life-saving Therapies. Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT) and Sparkasse Jena-Saale-Holzland count on an innovative therapeutic concept from Jena". Erfurt

Region Region Thüringen (federal state)
  Country Germany
Organisations Organisation SmartDyeLivery GmbH
  Organisation 2 Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT)
  Group Thuringia (govt region)
Products Product nanoparticle technology
  Product 2 business development (state/region)
Index term Index term SmartDyeLivery–SEVERAL: investment, 201805 financing round from new investor STIFT + existing investors bm|t + Sparkasse Jena-Saale-Holzland
Person Person Lehmann, Marc (SmartDyeLivery GmbH 20602 Managing Director)

Using tiny particles to transport active substances into diseased organs of the body - this approach is pursued by the SmartDyeLivery GmbH from Jena. With the patented concept based on functionalized nanoparticles, SmartDyeLivery was able to convince the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT), in addition to Sparkasse Jena-Saale-Holzland, which is further expanding its existing investment, and beteiligungsmanagement thüringen gmbh (bm|t), as a new investor in the Jena biotechnology company. Both the STIFT with the Board Members Professor Dr.-Ing. Werner Bornkessel and Dipl. Ing. Wolfgang Meyer and Managing Director Dr. Ing. Sven Günther as well as the Sparkasse Jena-Saale-Holzland with the Board Member Erhard Bückemeier and Investment Manager Tilo Mascher are convinced that this innovation from Thuringia, which can save lives, will be economically successful.

Nanoparticle-based technologies have great potential, especially in the medical sector. The SmartDyeLivery GmbH, in cooperation with the working groups around the founders and Jena university professors Ulrich S. Schubert and Michael Bauer, succeeded in developing nanoparticles that find their own way to the target in the body and release the transported active substances specifically and in a controlled manner only into the target cells. In addition to the specific transport of active agents, in the future, the function of affected organs will be determined with the help of nanoparticles.

In a first area of application, the company is focusing on the development of a specific therapeutic for patients with septic liver failure. Because of the lack of treatment options, these patients die in more than 90% of cases. The new therapy option currently under development could save more than 1,500 lives a year in Germany alone. "The latest preclinical data demonstrate the enormous potential already in the first possible area of application and show that we are on the right path," says Dr. Marc Lehmann, Managing Director of the Jena-based biotechnology company.

About the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT):

Within the framework of the ThEx project, the STIFT supports, promotes and accompanies innovative technology-oriented and innovative business start-ups in Thuringia. In addition, the STIFT supports selected high-tech foundations in the field of early-stage financing as a side investor. Here, the degree of innovation of the start-up idea and the entrepreneurial potential are in the foreground. The regional focus of investments is in Thuringia.

About the Sparkasse Jena-Saale-Holzland:

The Sparkasse Jena-Saale-Holzland has been a strong and reliable partner in the Jena and Saale-Holzland region for more than 185 years. Thanks to the large branch network, the consultants are close to their customers and make important decisions quickly and directly on site. From the current account over real estate brokerage and mortgage lending to corporate and commercial customer support, the Sparkasse offers everything from one source. As a public-law institute, it is committed to the common good, economic development in the region and the people who live here.

About the SmartDyeLivery GmbH:

The SmartDyeLivery GmbH develops specific, nanoparticle-based transporters for therapeutic, diagnostic and theranostic applications. The aim is to provide new treatment options for previously untreatable or difficult to treat diseases in order to save lives. The underlying technologies are patent-protected and have been awarded a special prize in the context of the Thuringian Innovation Award.

Further information can be found at


Dr. Marc Lehmann
Managing Director
SmartDyeLivery GmbH
Botzstraße 5
07743 Jena

Record changed: 2018-05-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for SmartDyeLivery GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top